Researchers led by the Institut Pasteur, Université Paris, have developed a vaccine that elicits anti-Immunoglobulin E ...

In patients with chronic spontaneous urticaria, biomarkers such as a positive chronic urticaria index and low blood histamine ...

Dupilumab enhances quality of life in chronic urticaria patients unresponsive to antihistamines. Find out how treatment can ...

CHEST guidelines on biologic management in severe adult asthma offers recommendations on choosing and switching among biologic therapies.

The FDA's approval of the new dosing option for Omlyclo addresses the diverse needs of patients with allergic and ...

Celltrion receives US FDA approval of 300mg strength of Omlyclo, the first and only interchangeable biosimilar to Xolair: Incheon, South Korea Thursday, December 4, 2025, 11:00 Hr ...

By blocking a molecule that pushes the immune system into overdrive, a vaccine protects mice from life-threatening ...

The result was IgE-K: a conjugate vaccine that teaches the immune system to recognize and neutralize IgE. When injected into ...

Celltrion secures US approval for 300mg OMLYCLO syringe, completes full PFS lineup Celltrion completes omalizumab prefilled ...

Celltrion, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new presentation of OMLYCLO® (omalizumab-igec), the first and only biosimilar designated as interchangeable ...

Celltrion said on the 25th that Omlyclo (OMLYCLO), a treatment for chronic spontaneous urticaria launched in Europe in Sep., has been released in major countries, including Germany, Spain, the United ...

The European Commission (EC) has granted a line extension in the European Union (EU) for Celltrion’s Omlyclo™ (omalizumab), Europe’s first and only omalizumab biosimilar, for the 300 mg/2ml prefilled ...